2018-11-15T09:01:07-06:00 2017-12-31 861065772 Deloitte Tax LLP 695 Town Center Drive Suite 1200 Costa Mesa CA 926261924 990 2017-01-01 330328688 La Jolla Institute for Allergy & Immunology LAJO 8587526500 9420 Athena Circle La Jolla CA 920371387 Jennifer Keyes CFO 8587526500 2018-11-15 1 John Sadoff Jr P00540589 7144367100 167.219.48.58 2018-11-15 02:29:19 US P BBC6FF48F749624228983DC5C77016F783C914CC CE2E37D982145188185ED530D22A0BCB5FB961D3 2017 2019-02-21 02:37:17Z Jennifer Keyes 9420 Athena Circle La Jolla CA 920371387 57462019 0 X www.lji.org X 1988 CA Biomedical research dedicated to improving human health through studies of the immune system. 25 24 418 99 305173 125666 51251936 49333077 6329766 5797546 293653 885432 1528905 2014061 59404260 58030116 10000 7000 0 0 27887172 30484441 0 0 704304 30084309 27785468 57981481 58276909 1422779 -246793 38148822 37144519 10525525 9768015 27623297 27376504 At La Jolla Institute, our scientists focus on understanding how the immune system works in order to promote human health and prevent disease. Our discoveries apply to many diseases, ranging from diabetes to heart disease, infectious diseases to cancer. 0 0 50825367 7000 5797546 The La Jolla Institute for Allergy and Immunology ("LJI") is a private, nonprofit medical research organization that is recognized as a world leader in comprehensive research dedicated to understanding the intricacies and power of the immune system and applying that knowledge toward its goal of Life Without Disease.The Institute is home to 23 independent laboratories, each operated by a leading scientist handpicked for her creativity and pioneering spirit. Each of these labs is dedicated to understanding the far-reaching influence of the immune system and to training to the next generation of scientists, to promote human health and prevent a wide range of diseases. 50825367 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 1 104 0 1 418 1 1 1 0 0 0 0 0 0 0 0 0 X 25 24 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA CT NJ IL MA MI OH NY NC PA TX UT VA WI AZ GA RI X Jennifer Keyes 8587526500 9420 Athena Circle La Jolla CA 920371387 Pamela W Blakely Director 2.00 0.00 X 0 0 0 Richard S Bodman Director 2.00 0.00 X 0 0 0 Mark V Bowles Director 2.00 0.00 X 0 0 0 David A Brenner MD Director 2.00 0.00 X 0 0 0 Anthony Carr Director 2.00 0.00 X 0 0 0 Kristine Charton JD Director 2.00 0.00 X 0 0 0 Barton J Cohen Director 2.00 0.00 X 0 0 0 Michael D Coit Director 2.00 0.00 X 0 0 0 David Dominguez Director 2.00 0.00 X 0 0 0 Robert C Dynes PhD Director 2.00 0.00 X 0 0 0 Francois Ferre PhD Director (Start 02/10/17) 2.00 0.00 X 0 0 0 Sergio Jinich Director (End 04/03/2017) 2.00 0.00 X 0 0 0 Richard K Kornfeld Director 2.00 0.00 X 0 0 0 Robert W Mahley MD PhD Director 2.00 0.00 X 0 0 0 John E Major Director 2.00 0.00 X 0 0 0 Gail K Naughton PhD Director 2.00 0.00 X 0 0 0 Hiroshi Okazaki PhD Director 2.00 0.00 X 0 0 0 Hunt Pettit Director 2.00 0.00 X 0 0 0 Larry S Spitcaufsky Director 2.00 0.00 X 0 0 0 Thomas L Tullie Director 2.00 0.00 X 0 0 0 David L Steffy Director (Start 08/11/17) 2.00 0.00 X 0 0 0 Fred Wasserman MBA DrPH Director 2.00 0.00 X 0 0 0 David R Webb PhD Director 2.00 0.00 X 0 0 0 Herbert A Wertheim OK DSC Director (End 05/19/17) 2.00 0.00 X 0 0 0 Vanessa V Wertheim PhD MBA RN Director (Start 05/19/17) 2.00 0.00 X 0 0 0 Eric V Zwisler Director 2.00 0.00 X 0 0 0 Mitchell Kronenberg PhD President & CSO 40.00 0.00 X X 523837 0 59515 Jennifer K Keyes CFO 40.00 0.00 X 175019 0 35925 Amnon Altman Director, Scientific Affairs 40.00 0.00 X 321960 0 63339 Stephen Wilson EVP, Chief Administrative Officer 40.00 0.00 X 355522 0 73630 Hilde Cheroutre Division Head/Professor 40.00 0.00 X 278809 0 50180 Klaus Ley Division Head/Professor 40.00 0.00 X 344683 0 50161 Stephen P Schoenberger Professor 40.00 0.00 X 308279 0 69630 Alessandro Sette Center Head/Division Head/Pro 40.00 0.00 X 406128 0 66094 Catherine Hedrick Professor 40.00 0.00 X 308280 0 57605 3022517 0 526079 50 0 1 0 Thien Douglas Y 701 Colle e Ave Menlo Park CA 94025 Consultant to provide services and asses 310000 Pillsbury Winthrop Shaw Pittman LLP PO Box 742262 Los Angeles CA 900742262 Patent Related (Legal and Professional 220191 Ho Patrick 2436 Corte Azul Carlsbad CA 92009 Consulting service 182291 1903 Solutions LLC 2549 Eastbluff Dr Suite 378 Newport Beach CA 92660 IT Web Support for Forti Analyzer 126005 Moss-Adams LLP PO Box 101822 Pasadena CA CA 911891822 Auditor (audit the Organization's financ 106855 5 80000 33928700 15324377 49333077 Consortium Revenue 900099 5797546 5797546 5797546 317335 317335 756914 756914 -569735 1638 569735 -1638 568097 568097 Other Income 900099 951974 951974 Building Management 561700 267731 267731 Technical Services 541900 37442 37442 1257147 58030116 5797546 305173 2594320 7000 7000 1608747 1415697 167064 25986 22233965 19404728 2767840 61397 2234805 1949867 277116 7822 2828982 2405140 391910 31932 1577942 1376754 195665 5523 418176 372177 45999 205393 205393 937156 215546 346748 374862 135541 5051 130490 159447 123690 9432 26325 1121151 828299 285670 7182 6336188 5639207 696981 670522 582972 66928 20622 197174 170656 21689 4829 1701880 1701880 246819 242806 4013 UBIT taxes 52029 52029 Lab Supplies & Svcs 8001470 7820288 181182 Consortiums 5564371 5564371 Manuscripts Cost 1338350 601713 598813 137824 699801 397525 302276 58276909 50825367 6747238 704304 2267 1667 4812686 3731697 14197357 10840175 620781 894774 762088 933812 25814997 18690672 6383473 7124325 11370170 13618069 38148822 37144519 9560172 8817556 965353 950459 10525525 9768015 X 26866555 26619762 756742 756742 27623297 27376504 38148822 37144519 -246793 0 X 0 1 X 1 1 1 X The University of California San Diego San Diego CA 127911 124884 3027 7096625 3404979 3691646 18575461 15160809 3414652 15000 15000 7124325 X 57724943 0 57724943 305173 305173 58030116 57971736 0 57971736 305173 305173 58276909 Part X, Line 2: The Institute is subject to federal and state income taxes on unrelated business income as defined under IRC Sections 511 through 515. For each of the years ended December 31, 2017 and 2016, taxes are recorded when paid and no provision for income tax has been made. The Institute had no unrecognized tax benefits or liabilities as of December 31, 2017 and 2016. Part XI, Line 4b - Other Adjustments: Expenses Netted Against Revenue on Audited Financial Statements 305,173. Part XII, Line 4b - Other Adjustments: Expenses Netted Against Revenue on Audited Financial Statements 305,173. 1 South Asia 0 0 Program services Research 185045 Europe (including Iceland and Greenland) 0 0 Program services Research 462396 South America 0 0 Program services Research 71629 East Asia and the Pacific 0 0 Program services Research 14895 Sub-Saharan Africa 0 0 Program services Research 144009 0 0 0 0 0 0 877974 0 877974 0 0 0 0 0 0 1 JDRF 5665 Oberlin Drive Suite 106 San Diego CA 92121 231907729 501(c)(3) 6000 To Cure Type I Diabetes and Promiss Ball 2017. 1 0 Part I, Line 2: LJI supports certain charities whose mission is inline with our research. This support is not in the form of grants, but rather contributions. Therefore, documentation exists over payment of contributions. Formal monitoring and selections procedures not considered necessary. X X X X 0 0 0 0 0 0 0 0 0 Mitchell Kronenberg PhD President & CSO 491045 0 0 0 32792 0 40500 0 19015 0 583352 0 0 0 Jennifer K Keyes CFO 160256 0 0 0 14763 0 26363 0 9562 0 210944 0 0 0 Amnon Altman Director, Scientific Affairs 283954 0 0 0 38006 0 40500 0 22839 0 385299 0 0 0 Stephen Wilson EVP, Chief Administrative Officer 336122 0 0 0 19400 0 40500 0 33130 0 429152 0 0 0 Hilde Cheroutre Division Head/Professor 274455 0 0 0 4354 0 40500 0 9680 0 328989 0 0 0 Klaus Ley Division Head/Professor 308928 0 0 0 35755 0 40500 0 9661 0 394844 0 0 0 Stephen P Schoenberger Professor 288431 0 0 0 19848 0 40500 0 29130 0 377909 0 0 0 Alessandro Sette Center Head/Division Head/Pro 385380 0 0 0 20748 0 40500 0 25594 0 472222 0 0 0 Catherine Hedrick Professor 290803 0 0 0 17477 0 40500 0 17105 0 365885 0 0 0 SEE PART V 0 Sch L, Part IV, Business Transactions Involving Interested Persons: (a) Name of Person: Hilde Cheroutre(b) Relationship Between Interested Person and Organization: Spouse of President and CSO (c) Amount of Transaction $278,809(d) Description of Transaction: Full Time Employee(e) Sharing of Organization Revenues? = No(a) Name of Person: Kyowa Kirin Pharmaceutical Research, Inc.(b) Relationship Between Interested Person and Organization:KKR is a Substantial Contributor to the Organization.(c) Amount of Transaction $3,416,575(d) Description of Transaction: Research Funding, Facility Rent, Cost Reimbursements (e) Sharing of Organization Revenues? = No Form 990, Part III, Line 4a; The Institute was recently ranked among the top five organizations with the greatest research impact in immunology worldwide by the rating agency Thomson-Reuters. In addition, four of its scientists are among the most highly cited immunologists in the world-a distinction held by less than half of one percent of all publishing scientists. One of them, Prof. Dr. Shane Crotty's made the list for the second year in a row in recognition of his pioneering studies on vaccine-related immunology. Illustrating the caliber and impact of LJI's researchers, Dr. Alessandro Sette's team has been named Best Academic Research Team as part of the 10th Vaccine Industry Excellence Awards at the World Vaccine Congress 2017. The ViE Awards celebrate the outstanding contributions and achievements of leaders who continually set standards of excellence and advocacy in vaccine development. Dr. Klaus Ley has been selected as the 2017 winner of the Eugene M. Landis Award, the Microcirculatory Society's top honor, in recognition of his pioneering work in vascular biology and microcirculation. In 2017, La Jolla Institute launched the Center for Asthma Prevention and Treatment dedicated to understanding, treating and solving the problem of asthma. A joint endeavor between LJI and UC San Diego Health, the center will bring together patients, clinicians and researchers to accelerate the development of individualized asthma treatments based on patient-specific disease markers. The wide range of expertise coming together at the Center for Asthma Prevention and Treatment made an immediate impact. It allowed a team of physicians, scientists and bioinformaticians affiliated with the center to successfully compete for an $8.5 million grant to establish one of only ten PrecISE Network Clinical Centers nationwide. The PrecISE Network is an initiative funded by the National Institutes of Health/National Heart, Lung and Blood Institute, to advance precision medicine for patients with severe and exacerbation-prone asthma. 2017 Notable Research Results In 2017, LJI research teams made discoveries meriting publication in leading peer-reviewed scientific journals 135 papers in all, continuing a trend of very high productivity. 40 of them appeared in high impact journals, which is a measure of the research's pioneering nature and influence. Together, they illustrate the range and power of immunology research, the caliber of LJI's faculty and their impact on a broad group of human health issues. Some of the highlights among papers published in 2017 include: Dr. Alessandro Sette and his collaborators found the first direct evidence that autoimmunity--in which the immune system attacks the body's own tissues--plays a role in Parkinson's disease, the neurodegenerative movement disorder. The findings raise the possibility that the death of neurons in Parkinson's could be prevented by therapies that dampen the immune response. The idea that a malfunctioning immune system contributes to Parkinson's dates back almost 100 years. But until now, no one had been able to connect the dots. Plus, scientists long thought that neurons were protected from autoimmune attacks. Dr. Sette's findings show that two fragments of alpha-synuclein, a protein that accumulates in the brain cells of people with Parkinson's, can activate the T cells involved in autoimmune attacks. The study was published today in the June edition of Nature. Dr. Pandurangan Vijayanand and his team demonstrated that tumor immune fitness determines survival of lung cancer patients. In recent years, immunotherapy, a new form of cancer therapy that rouses the immune system to attack tumor cells, has captivated the public's imagination. When it works, the results are breathtaking. But more often than not it doesn't, and scientists still don't know why. Publishing in the June 2017 issue of Nature Immunology, Dr. Vijayanand's team identified a subpopulation of T cells in tumors known as tissue-resident memory T cells (TRM) as an important distinguishing factor between cancer patients whose immune system mounts an effective anti-tumor response and those who are unable to do so. Their finding emerged from the first large-scale effort to profile the gene expression patterns of cytotoxic T cells isolated directly from patients' tumors. Dr. Klaus Ley's lab provided new insight into how neutrophils, the immune system's EMTs, spend most of their lives racing through the bloodstream constantly on the lookout for bacteria and other foreign invaders. Once they arrive at infiltrated tissues, they halt on a dime and slip through the vessel wall to reach the site of infection. Dr. Klaus Ley and his colleagues developed a sophisticated intra-vital imaging method that allowed them to watch in real time how neutrophils control their speed as they roll along the walls of blood vessels. The dramatic, real-time footage shows in great detail how neutrophils throw out tube-like tethers to anchor themselves to avoid being swept away by blood rushing by at high speed. As neutrophils gently roll along, tether after tether is peeled loose and slung forward like a lasso to gain new leverage, slowing them down enough to exit the blood vessel. A study by Dr. Shane Crotty and his collaborators established important benchmarks for HIV vaccine candidates. The development of a vaccine that protects against HIV infections has proven extraordinarily difficult. One of the reasons is that nave precursor B cells that can give rise to mature B cells producing broadly neutralizing antibodies-a requirement for a successful antibody-based HIV vaccine-are considered to be exceedingly rare within the average human. Publishing in the December 201 issue of the journal Immunity, Dr. Crotty and team were able to show that despite their low frequency these B cell precursors can be successfully primed to prevail over their B cell competitors under the right conditions. Earlier studies had detected these B cells in most humans but at very low frequencies, about one in a million and it had been unclear whether that was enough to elicit an effective immune response. By providing an answer, the current study closes the knowledge gap about competition between different immune responses and establishes defined benchmarks vaccine candidates should be compared against for consideration before they are put into clinical trials. Dr. Klaus Ley successfully mirrored the breadth of genetic and immunological diversity found in the human population in the lab by using a panel of about 100 different inbred mouse strains instead of just one. The new approach successfully replicates natural human immune variation in the lab and allowed Dr. Ley and his team to identify a molecular fingerprint that successfully predicted individual people's susceptibility to inflammatory disease as well as survival of patients with certain cancers. Traditionally, researchers have relied on genetically identically mouse strains to gain insight into the complex world of human diseases while reducing what is known as experimental noise. But in contrast to these mice, not two people are genetically alike. As a direct result many promising drug candidates fizzled in the face of human genetic diversity. Competitive Research Grant Funding & Research Awards & Distinctions In 2017, La Jolla Institute scientists continued to attract increasing numbers of competitively awarded research grants attesting to the high level of research productivity present at the Institute. One example is Dr. Catherine (Lynn) Hedrick, Ph.D., a Professor in the Division of Inflammation Biology, who has been awarded a five-year, $13 million grant by the National Institutes of Health to lead a collaborative research program project to study how functional changes in immune cells contribute to atherosclerosis. The end goal of the study is to identify novel therapeutic strategies targeting immune cell function to reduce cardiovascular disease. During 2017, LJI scientists worked with the support of 152 grants, contract and fellowships. The granting institutions included: National Institutes of Health, Boston Children's Hospital, Benaroya Research Institute at Virginia Mason, University of California Berkeley, Case Western University, Cedars Sinai Medical Center, Dana-Farber Cancer Institute, Albert Einstein College of Medicine, Emory University, University of Georgia, University of Wisconsin, Ichan School of Medicine at Mount Sinai, Sanford Burnham Prebys Medical Discovery Institute, The Scripps Research Institute, University of Florida, University of Alabama at Birmingham, University of California Los Angeles, University of California San Diego, University of North Carolina, University of Washington, University of Arizona, EU/European Commission, Lurie Children's Hospital of Chicago, American Heart Association, Arthritis National Research Foundation, Crohn's and Colitis Foundation of America, Cancer Research Institute, Immune Deficiency Foundation, Jane Coffin Childs Memorial Fund for Medical Research, Jeffrey Modell Foundation, Johns Hopkins University, Leukemia and Lymphoma Society, The Michael J. Fox Foundation, National Parkinson's Foundation, Oregon Health Science University, The Pew Charitable Trusts, Rady Children's Hospital - San Diego, Thrasher Research Fund, University of Cape Town, University of Miami, American Lung Association, Human Vaccines Project, and the Vasculitis Foundation. With new and recurring grant support, the Institute received more than $44 million in research funding in 2017, which is supplemented by corporate funding sources as well as philanthropic support. Form 990, Part VI, Section A, line 2 Mitchell Kronenberg, Ph.D. and Hilde Cheroutre have a family relationship. Form 990, Part VI, Section B, line 11b In accordance with written Institute Policy, a draft of Form 990 is provided to all Board Members for their review and comment approximately 10 days prior to filing. This provides an opportunity for members of the Board to ask questions and obtain additional information. Comments and suggested changes to the draft are incorporated into the final version of Form 990. Form 990, Part VI, Section B, line 12c The Institute administers three separate conflict of interest policies applying to 1) The Board of Directors, 2) Faculty and Senior Administration, and 3) An investigator financial conflict of interest policy required under National Institutes of Health Regulations. The Institute regularly and consistently monitors and enforces these policies in accordance with written procedures, which include the completion of disclosure forms by covered individuals, evaluation of completed forms by a designated conflict review officer, and as necessary, further evaluation and determination by a designated conflict review committee. If a conflict is determined, a management plan is designed and monitored for the specific situation. Such plan may require the covered individual to eliminate the conflict. Form 990, Part VI, Section B, line 15 Compensation decisions for the institute's CEO and other key employees are Made annually. Adjustments, if any, typically take effect on a January 1st Cycle. For these purposes, the institute's Human Resources Department Obtains relevant market comparability data for each position on an annual Basis. The institute also periodically engages an independent compensation Consulting firm to perform compensation studies for key individuals and to Evaluate the institute's executive compensation and benefits programs for Reasonableness. In accordance with its charter, the compensation committee Of the board of directors reviews and discusses this information, and the Performance of the institute's CEO and key employees, and formulates Recommended compensation actions to the full board of directors. The board Of directors reviews these recommendations and related information in Deciding compensation levels for each position. Form 990, Part VI, Section C, line 19 The Institute makes its governing documents, Conflict of Interest Policy, and Financial Statements available to the public upon request. Summarized Financial data is also made available as part of the Institute's Annual Report, which is widely distributed, and can be downloaded from the Institute's web site.